Replimune to Resubmit Rejected Drug for FDA Approval After Shakeup

Replimune plans to resubmit its lead drug for FDA approval after it was twice rejected, following a shakeup at the regulatory agency. The company's stock surged on the news of the planned resubmission.

29 May, 12:51 — 29 May, 12:51

Post Share

Sources

Showing 1 of 2 sources

cnbcMostly Factual72d ago

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.

Read full article →

Coverage Timeline

First report: seeking-alpha · 29 May, 12:22|Full coverage: 2 · 29m|Window: 29m

Left-leaningCenterRight-leaning

seeking-alpha29 May, 12:22First to report

Replimune surges on plans to resubmit lead drug for FDA review

cnbc29 May, 12:51Latest update

PERSPECTA

PERSPECTA

Replimune to Resubmit Rejected Drug for FDA Approval After Shakeup

Sources

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

Coverage Timeline

Replimune surges on plans to resubmit lead drug for FDA review

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

Related Stories

Europe Begins Lithium Mining in Finland

Single Mother Executive Details Monthly Finances

Bloomberg Weekend Roundup of Missed Headlines

Romania Sinks Barges in Danube to Support Cernavodă Nuclear Plant

PERSPECTA